Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,864 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics in Healthy Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating Eliglustat's Effects on Pharmacokinetics, Safety & Tolerability of Digoxin in Healthy Adults

NCT01357811
View directory record Official record
Conditions
Healthy Volunteer
Interventions
eliglustat; digoxin, digoxin
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

NCT05169671
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ATH-1020, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers

NCT01101646
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
rabeprazole sodium
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food-effect Study of Ecopipam Pharmacokinetics

NCT06669091
View directory record Official record
Conditions
Food-effect
Interventions
Ecopipam tablet
Drug
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

NCT05408780
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AC-OLE-01-VA
Drug
Lead sponsor
Cerecin
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

NCT00575367
View directory record Official record
Conditions
Bacterial Infections, Eye Infections
Interventions
AzaSite (azithromycin ophthalmic solution), Vigamox (moxifloxacin hydrochloride ophthalmic solution)
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2011 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

NCT01827657
View directory record Official record
Conditions
Hepatitis C
Interventions
GSK2336805
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 74 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 8, 2026, 1:39 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

NCT02047656
View directory record Official record
Conditions
Part 1 - Healthy Volunteers, Part 2 - Patients With Hypertension
Interventions
LFF269, Placebo to LFF269
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2016 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

NCT01489345
View directory record Official record
Conditions
Healthy
Interventions
ONO-2952, ONO-2952 Matching Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Interaction Study of LY3200882 in Healthy Participants

NCT03792139
View directory record Official record
Conditions
Healthy
Interventions
LY3200882, Itraconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects

NCT02855177
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, PF-06427878
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Glendale, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

NCT04016077
View directory record Official record
Conditions
Hepatic Impairment, Healthy Participants
Interventions
PF-06651600 30 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants

NCT04567667
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C] BMS-986278, Kinevac®
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

NCT02334800
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
Palbociclib 75 mg Capsule
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

NCT01761565
View directory record Official record
Conditions
Plasma Concentrations
Interventions
Single dose of SUF NT 15 mcg, 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

NCT02018536
View directory record Official record
Conditions
Healthy
Interventions
GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

NCT04545944
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan, Midazolam
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants

NCT02882009
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Gantenerumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects

NCT00983099
View directory record Official record
Conditions
Healthy
Interventions
Neramexane
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
20 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

NCT07032272
View directory record Official record
Conditions
Autoimmune and Chronic Inflammatory Diseases
Interventions
remibrutinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

NCT04914936
View directory record Official record
Conditions
Healthy Participants
Interventions
ACP-196, Calcium carbonate, Omeprazole, Rifampin
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants

NCT02982707
View directory record Official record
Conditions
Thrombosis
Interventions
BMS-986177
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117

NCT02018510
View directory record Official record
Conditions
Healthy, HIV
Interventions
1 mg/kg, single dose IV administration of 3BNC117, 3 mg/kg, single dose IV administration of 3BNC117, 10 mg/kg, single dose IV administration of 3BNC117, 30 mg/kg, single dose IV administration of 3BNC117, 10 mg/kg, two doses IV of 3BNC117, 30 mg/kg, two doses IV of 3BNC117
Biological
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Oct 8, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032

NCT01019070
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
BMS-650032
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Anaheim, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Oct 8, 2026, 1:39 AM EDT